)
Edge31 Oct 2025
Rolls-Royce: Full Thrust Ahead
From century-old crafted perfection to pandemic shock and reset, Rolls-Royce's story is shaped by heritage, turbulence, and a disciplined climb back.
Royalty Pharma (RPRX) investor relations material
Royalty Pharma Q3 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q3 2025 earnings summary5 Nov, 2025
Executive summary
Achieved 11% year-over-year growth in both Portfolio and Royalty Receipts for Q3 2025, driven by key products like Voranigo, Tremfya, and the cystic fibrosis franchise.
Raised full-year 2025 Portfolio Receipts guidance to $3,200–$3,250 million, reflecting 14–16% expected growth.
Deployed $1 billion in Q3 and $1.7–$2.0 billion in the first nine months of 2025 on major royalty transactions and development-stage therapies.
Repurchased 35 million shares for $1.15–$1.2 billion in the first nine months of 2025, with 4 million shares repurchased for $152 million in Q3.
Completed internalization of management in May 2025, incurring one-time costs and transitioning to an integrated operating model.
Financial highlights
Portfolio Receipts and Royalty Receipts both grew 11% year-over-year in Q3 2025, reaching $814 million and $811 million, respectively.
Adjusted EBITDA for Q3 2025 was $779 million, with Portfolio Cash Flow at $657 million and a margin of 81%.
Net income attributable to shareholders for Q3 2025 was $288 million, down from $544 million in Q3 2024.
Cash and cash equivalents stood at $939 million as of September 30, 2025; total debt was $9.2 billion with a weighted average cost of 3.75%.
Weighted average share count declined to 560 million, down from 593 million in Q3 2024.
Outlook and guidance
Full-year 2025 Portfolio Receipts guidance raised to $3,200–$3,250 million, up from $3,050–$3,150 million, reflecting 14–16% growth.
Milestones and other contractual receipts expected to be $125 million for 2025.
Operating and professional costs projected at 9–9.5% of Portfolio Receipts; interest paid expected to be $275 million in 2025 and $350–$360 million in 2026.
Guidance assumes no major adverse events or significant FX changes and excludes contributions from transactions announced after the press release date.
Minimal royalties expected from Promacta in 2026 due to generic launches.
Contribution of new royalty assets to 2026 guidance
How new debt impacts weighted average cost of debt?
Sustainability of key royalty growth drivers
Detail risk mitigation for development-stage deals
How does Royalty Pharma's structure impact deal-making
Update on China market strategy
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Royalty Pharma earnings date
Q4 202511 Feb, 2026
Next Royalty Pharma earnings date
Q4 202511 Feb, 2026
The essential earnings season companion
The #1 app for qualitative research. Live earnings calls, AI chat, transcripts, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
)
)
Frequently asked questions
Royalty Pharma plc operates as a buyer of biopharmaceutical royalties and a funder of innovations in the biopharmaceutical industry in the United States. The company's royalty acquisition segment engages in the acquisition of royalty streams from pharmaceutical companies. Its funding segment provides equity or loan financing to biotechnology companies developing innovative methods for the treatment of cancer, inflammatory disease, obesity, diabetes, and other metabolic disorders.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage